Dk. Tack et al., Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia, BONE MAR TR, 28(9), 2001, pp. 895-897
Citations number
8
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Mylotarg (gemtuzumab zogamicin) is a conjugated monoclonal antibody that ha
s recently become available for use in patients with relapsing or refractor
y acute myeloid leukemia. Reversible hepatotoxicity is common after adminis
tration. We describe the first report of hepatic veno-occlusive disease (HV
OD) developing after Mylotarg infusion in a patient who underwent hematopoi
etic stem cell transplantation 8 months earlier. Certain antineoplastic age
nts have been implicated as a cause of HVOD, but the disease is most common
ly seen within 30 days after hematopoietic stem cell transplantation. The p
ossible association between Mylotarg infusion and HVOD is discussed.